The Beauty Health Company Stock Price, News & Analysis

The Beauty Health Company (NASDAQ:SKIN) has launched the Hydrafacial Advisory Councils and Ambassador Network, bringing together leading plastic surgeons, dermatologists, aesthetic practitioners, and estheticians to guide the company's future development.

The initiative aims to enhance product innovation, education programs, and clinical research through real-world insights. The councils will be led by three inaugural chairs: Ted Lain, MD, MBA; Blaklee Paige Smith, MSN, APRN; and Kelly Horton-Beeman, LE.

This strategic move builds upon Hydrafacial's existing professional development initiatives, including their HFX Training Programs which have trained over 60,000 providers globally. The company also maintains partnerships with various professional organizations and offers scholarship programs for estheticians.

The Beauty Health Company (NASDAQ:SKIN), owner of Hydrafacial™, has launched its Hydrafacial Advisory Councils and Ambassador Network, comprising leading plastic surgeons, dermatologists, aesthetic practitioners, and estheticians. The initiative aims to enhance product development, education, and clinical excellence.

Led by CEO Marla Beck, the program features inaugural council chairs including Ted Lain, MD, MBA, Blaklee Paige Smith, and Kelly Horton-Beeman. The councils will guide innovation, treatment protocols, and clinical research while supporting peer-to-peer learning initiatives. This strategic move builds upon Hydrafacial's existing provider support programs, including their HFX Training Programs which have trained over 60,000 providers globally.

BeautyHealth (NASDAQ: SKIN) reported Q2 2025 financial results, showing mixed performance with net sales of $78.2 million, down 13.7% year-over-year, but improved profitability metrics. The company achieved net income of $19.7 million, up from $0.2 million in Q2 2024, and Adjusted EBITDA of $13.9 million compared to $(5.2) million last year.

Key highlights include gross margin improvement to 62.8% (vs 45.2% in Q2 2024), successful debt restructuring, and an active install base of 35,193 units. The company raised its 2025 guidance, projecting net sales of $285-300 million and Adjusted EBITDA of $27-35 million. BeautyHealth also successfully launched HydraFillic with Pep9™ Booster and reported strong consumables performance, representing over 70% of revenue.

["Net income increased significantly to $19.7M from $0.2M YoY", "Gross margin improved to 62.8% from 45.2% YoY", "Adjusted EBITDA turned positive to $13.9M from $(5.2)M YoY", "Consumables now represent over 70% of revenue, showing recurring revenue strength", "Raised full-year 2025 guidance", "Successfully restructured debt obligations"]

BeautyHealth (NASDAQ:SKIN), the company behind Hydrafacial™, has scheduled its second quarter 2025 financial results announcement for August 7, 2025, after market close. The company will host an investor conference call at 4:30 p.m. Eastern Time to discuss the results.

Investors can access the live webcast and supporting materials through BeautyHealth's investor relations website. A recording will be available approximately three hours after the call concludes.

The Beauty Health Company (NASDAQ:SKIN) has launched HydraFillic with Pep9™ Booster, a new peptide-powered skin treatment for their Hydrafacial brand. The innovative booster features a proprietary complex of nine peptides clinically proven to improve fine lines, wrinkles, and skin firmness. Clinical testing demonstrated significant improvements in skin firmness, elasticity, hydration, and barrier health. Consumer perception data showed impressive results with 100% reporting improved skin firmness, 96% noting enhanced skin glow, and 93% experiencing tighter, smoother, and deeply hydrated skin. The product combines Pep9™ complex, Triple Hyaluronic Acid Complex, and fruit extracts with Vitamin B5. Hydrafacial's treatment system, which includes seven skin therapies, maintains a strong market presence with over 35,000 active devices globally.

BeautyHealth (NASDAQ: SKIN) has reached a significant milestone with 35,000 Hydrafacial devices installed worldwide, solidifying its leadership in the hydradermabrasion category. The company delivered approximately 5 million treatments last year, performing 1.5 treatments every second globally. Hydrafacial ranks as the second most recognized facial treatment in the U.S. with impressive metrics including a 96% "Worth It" rating on RealSelf and a 52 Net Promoter Score. The treatment combines seven skin therapies: lymphatic drainage, gentle peel, extractions, microdermabrasion, personalized booster, LED light therapy, and deep hydration. The company's success is supported by its portfolio of 175+ patents and its ability to drive approximately 7% of new patients to medical spas and aesthetic practices annually.

BeautyHealth (NASDAQ:SKIN) has announced a significant debt refinancing through privately negotiated exchange agreements. The company will exchange $413.2 million of its existing 1.25% convertible senior notes due 2026 for $250.0 million of new 7.95% convertible senior secured notes due 2028, plus approximately $143.4 million in cash. The new notes will be senior, secured obligations guaranteed by certain subsidiaries and feature an initial conversion rate of 349.6503 shares per $1,000 principal amount, equivalent to a conversion price of about $2.86 per share. The transaction, expected to close around May 27, 2025, aims to extend debt maturity and strengthen the company's financial position for growth initiatives.

BeautyHealth (NASDAQ: SKIN) reported Q1 2025 financial results with net sales of $69.6 million, down 14.5% from Q1 2024, primarily due to lower delivery systems sales. Despite macroeconomic pressures, the company showed improved profitability metrics with gross margin increasing to 69.8% from 59.4% year-over-year. The company reported a net loss of $10.1 million compared to $0.7 million in Q1 2024, while Adjusted EBITDA improved to $7.3 million from $0.4 million. The active install base grew to 35,014 units from 32,530 in the prior year, supporting resilient consumables revenue. The company is transitioning its China operations to a distributor model and has updated its FY2025 guidance to $270-300 million in net sales and $15-25 million in Adjusted EBITDA.

BeautyHealth (NASDAQ: SKIN), the company behind Hydrafacial, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will host an investor conference call at 4:30 p.m. Eastern Time following the results release.

Investors and interested parties can access:

• Live webcast of the call on BeautyHealth's investor relations website
• Supporting materials for the presentation
• Recording of the call (available approximately three hours after conclusion)

The company maintains transparency through various communication channels, including SEC filings, press releases, public conference calls, and their investor relations website, ensuring compliance with Regulation FD disclosure obligations.